Literature DB >> 20384965

The role of glia and the immune system in the development and maintenance of neuropathic pain.

Ricardo Vallejo1, Dana M Tilley, Laura Vogel, Ramsin Benyamin.   

Abstract

Neuropathic pain refers to a variety of chronic pain conditions with differing underlying pathophysiologic mechanisms and origins. Recent studies indicate a communication between the immune system and the nervous system. A common underlying mechanism of neuropathic pain is the presence of inflammation at the site of the damaged or affected nerve(s). This inflammatory response initiates a cascade of events resulting in the concentration and activation of innate immune cells at the site of tissue injury. The release of immunoactive substances such as cytokines, neurotrophic factors, and chemokines initiate local actions and can result in a more generalized immune response. The resultant neuroinflammatory environment can cause activation of glial cells located in the spinal cord and the brain, which appear to play a prominent role in nociception. Glial cells, also known as neuroglia, are nonconducting cells that modulate neurotransmission at the synaptic level. Glial cells can be subdivided into two primary categories: microglia and macroglia, which include astrocytes and oligodendrocytes. Astrocytes and microglia are known to play a role in the development, spread, and potentiation of neuropathic pain. Following peripheral nociceptive activation via nerve injury, microglia become activated and release pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6, thereby initiating the pain process. Microglia propagate the neuroinflammation by recruiting other microglia and eventually activating nearby astrocytes, which prolongs the inflammatory state and leads to a chronic neuropathic pain condition. Our review focuses on the role of glia and the immune system in the development and maintenance of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384965     DOI: 10.1111/j.1533-2500.2010.00367.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  118 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

2.  Naloxone and ouabain in ultralow concentrations restore Na+/K+-ATPase and cytoskeleton in lipopolysaccharide-treated astrocytes.

Authors:  Johan Forshammar; Linda Block; Christopher Lundborg; Björn Biber; Elisabeth Hansson
Journal:  J Biol Chem       Date:  2011-07-12       Impact factor: 5.157

3.  Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Haijun Zhang; Hongmei Zhang; Alyssa K Kosturakis; Abdul Basit Jawad; Patrick M Dougherty
Journal:  J Pain       Date:  2014-04-19       Impact factor: 5.820

4.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

5.  Suppression of microRNA-155 attenuates neuropathic pain by regulating SOCS1 signalling pathway.

Authors:  Yi Tan; Jun Yang; Kai Xiang; Qindong Tan; Qulian Guo
Journal:  Neurochem Res       Date:  2014-12-09       Impact factor: 3.996

6.  Pharmacological activation of heme oxygenase (HO)-1/carbon monoxide pathway prevents the development of peripheral neuropathic pain in Wistar rats.

Authors:  Krishna Reddy V Bijjem; Satyanarayana S V Padi; Pyare lal Sharma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 7.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

8.  MiR-19a targets suppressor of cytokine signaling 1 to modulate the progression of neuropathic pain.

Authors:  Conghui Wang; Qi Jiang; Min Wang; Dong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain.

Authors:  Nan Gu; Ukpong B Eyo; Madhuvika Murugan; Jiyun Peng; Sanjana Matta; Hailong Dong; Long-Jun Wu
Journal:  Brain Behav Immun       Date:  2015-11-11       Impact factor: 7.217

10.  Elevation of tumor necrosis factor α in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis.

Authors:  F Begum; W Zhu; C Cortes; B MacNeil; M Namaka
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-14       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.